Cladribine - MS Research Australia

Cladribine

Cladribine

Administration Route: Oral
Injection site:  N/A
Frequency: Two treatment courses, twelve months apart
TGA approval date: 1/09/2010
PBS listed: Yes
Mechanism of action As a purine analog, it is a synthetic chemotherapy agent that targets lymphocytes and selectively suppresses the immune system, its exact mechanism of action in MS is not clear.
%reduction in relapse rate, impact of progression 57.6% (3.5mg/kg) or 54.5% (5.25mg/kg) reduction.
Pregnancy Category D
Safe in Pregnancy Interferes with DNA synthesis and suspected to cause or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage.

Pregnancy should be avoided during treatment and for at least 6 months after the last dose.

Men being treated should take precautions to prevent pregnancy of their partner.

Breastfeeding (information predominatly from  LACTMED database) It is not known if cladribine is excreted in human milk. Because many meidcations are excreted in human milk and there is no published experience with cladribine during breastfeeding, it should be avoided during breastfeeding.
Monitoring requirements Careful hematologic monitoring is recommended. People are advised to follow the standard cancer screening guidelines.
Potential side effects (not a comprehensive list) Reduction in white blood cells, infections, nausea, diarrhoea, headache, muscle/joint pain, fatigue.
Manufacturer Merck Serono
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search